Insulins
PreclinicalSmall molecule
Eli LillyInsulins is one of 79 small molecule programs targeting Acute Pancreatitis. It is currently in Preclinical.
3
Indications
3
Total Trials
0
Active Trials
78
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
885 competitors in Type 2 Diabetes
#DrugCompanyPhaseTrials
1Byetta
AstraZenecaPreclinical
Jardiance
Boehringer IngelheimPreclinical
Inspra
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Inderal
WWyeth-Lederle Vaccines
Preclinical
Pravachol
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Preclinical
Cecon
MMcGuff Pharmaceuticals, Inc.
Preclinical
Acipimox
Boehringer IngelheimPreclinical
GLP-1
RRigshospitalet, Denmark
Preclinical
Henagliflozin
TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Preclinical
Glucagon-Like Peptide-1 (GLP-1)
Novo NordiskPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Heart Failure1 trial
Incretin-based Drugs and the Risk of Heart Failure
Completed·CCanadian Network for Observational Drug Effect Studies, CNODES··NCT02456428·1,499,650 enrolled
Acute Pancreatitis1 trial
Incretin-based Drugs and Acute Pancreatitis
Completed·CCanadian Network for Observational Drug Effect Studies, CNODES··NCT02476760·1,417,914 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Insulins. EMBL-EBI & Wellcome Sanger Institute.
- [4]